miR-138 inhibited cancer cell growth and tumorigenesis in non-small cell lung cancer and nasopharyngeal cancer by targeting 3-phosphoinositide-dependent protein kinase-1 (PDK1) and CCND1 [38]–[40]. The gene discussed is CCND1; the disease is nasopharyngeal carcinoma.